Form 4: Immunome Director Sandra Swain Granted Stock Options Valued at $9.57 Per Share

Immunome Inc. Director Sandra M. Swain was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year, as part of her compensation.

Summary

• Sandra M. Swain, a Director of Immunome Inc. (IMNM), was granted 18,864 Director Stock Options.
• The transaction date for this grant was June 10, 2025.
• The exercise price for these options is $9.57 per share.
• The options will vest in four equal quarterly installments, commencing from June 10, 2025, and continuing until the one-year anniversary of the grant date.
• Vesting is contingent upon Ms. Swain's continuous service with Immunome Inc. on each respective vesting date.
• The expiration date for these stock options is June 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The options have a long expiration date (June 9, 2035), providing ample time for the stock price to appreciate above the exercise price.

Negatives

• The options are not immediately exercisable and are subject to a one-year quarterly vesting schedule, meaning the full benefit is not immediate.
• The value of the options is dependent on the future stock price of Immunome Inc. exceeding the $9.57 exercise price.

Future Outlook

The document primarily details a past compensation grant and its vesting schedule, rather than providing a broad future outlook for the company's operations or financial performance. The vesting schedule indicates a commitment to continuous service for at least one year from the grant date.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of leadership with those of shareholders. This practice is particularly prevalent in growth-oriented sectors like biotech where long-term value creation is a key focus.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like Immunome Inc.
• The vesting schedule of four quarterly installments over one year is a common structure for equity grants, designed to encourage continued service and long-term commitment.
• The exercise price being set at a specific value ($9.57) is typical for stock options, often reflecting the stock price at or near the grant date.

Corporate Governance

Related Party Transactions

• The grant of 18,864 stock options to Sandra M. Swain, a Director of Immunome Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The stock options will vest in four quarterly installments, commencing June 10, 2025, subject to continuous service.
• The options will be exercisable upon vesting and will expire on June 9, 2035.

Key Dates

Keywords

Immunome Inc., IMNM, Sandra M. Swain, Director, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4, Vesting Schedule, Biotechnology, Pharmaceuticals